Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.

Cheng H, Jiang X, Zhu X, Zhu X, Li C, Cao M, Zhou Q, Deng S, Wu W

Obesity (Silver Spring, Md.)24 Feb 2026Cited by 1 (Europe PMC)

PMID41736232DOI10.1002/oby.70153PepBankPUB-41736232

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In people with obesity, liraglutide and calorie restriction had no significant between-group interaction for pancreatic fat fraction (interaction p = 0.560).
In plain wordsIn people with obesity, liraglutide and calorie restriction did not differ significantly for pancreatic fat.
Peptide
Liraglutide
Outcome
No significant changePancreatic fat fraction
Study
n = 46
Comparator
Calorie restricted diet
Analysis
Primary
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
3 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Report a problemFND-4173623201
02HumanNon-randomized trialEfficacy outcome
In people with obesity, liraglutide and calorie restriction had no significant between-group interaction for body weight (interaction p > 0.05).
In plain wordsIn people with obesity, liraglutide and calorie restriction did not differ significantly for body weight.
Peptide
Liraglutide
Outcome
No significant changeBody weight
Study
n = 46
Comparator
Calorie restricted diet
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
Report a problemFND-4173623202
03HumanNon-randomized trialEfficacy outcome
In people with obesity, liraglutide and calorie restriction had no significant between-group interaction for liver fat fraction (interaction p > 0.05).
In plain wordsIn people with obesity, liraglutide and calorie restriction did not differ significantly for liver fat.
Peptide
Liraglutide
Outcome
No significant changeLiver fat fraction
Study
n = 46
Comparator
Calorie restricted diet
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
Report a problemFND-4173623203
04HumanNon-randomized trialEfficacy outcome
In people with obesity, liraglutide and calorie restriction had no significant between-group interaction for visceral fat area (interaction p > 0.05).
In plain wordsIn people with obesity, liraglutide and calorie restriction did not differ significantly for visceral fat.
Peptide
Liraglutide
Outcome
No significant changeVisceral fat area
Study
n = 46
Comparator
Calorie restricted diet
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
Report a problemFND-4173623204
05HumanNon-randomized trialEfficacy outcome
In people with obesity, liraglutide and calorie restriction had no significant between-group interaction for HbA1c (interaction p > 0.05).
In plain wordsIn people with obesity, liraglutide and calorie restriction did not differ significantly for HbA1c.
Peptide
Liraglutide
Outcome
No significant changeHbA1c
Study
n = 46
Comparator
Calorie restricted diet
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
Report a problemFND-4173623205
06HumanNon-randomized trialEfficacy outcome
In people with obesity, liraglutide and calorie restriction had no significant between-group interaction for HOMA2-IR (interaction p > 0.05).
In plain wordsIn people with obesity, liraglutide and calorie restriction did not differ significantly for HOMA2-IR.
Peptide
Liraglutide
Outcome
No significant changeHOMA2-IR
Study
n = 46
Comparator
Calorie restricted diet
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
Report a problemFND-4173623206
07HumanNon-randomized trialEfficacy outcome
In people with obesity, liraglutide and calorie restriction had no significant between-group interaction for ISIM (interaction p > 0.05).
In plain wordsIn people with obesity, liraglutide and calorie restriction did not differ significantly for ISIM.
Peptide
Liraglutide
Outcome
No significant changeISIM
Study
n = 46
Comparator
Calorie restricted diet
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
Report a problemFND-4173623207

Studies that did not test the peptide alone12

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

08HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In people with obesity, pancreatic fat fraction significantly decreased over time across both calorie-restriction and liraglutide groups (time p < 0.001).
In plain wordsIn people with obesity, pancreatic fat fraction decreased over time across both calorie-restriction and liraglutide groups.
Peptide
Liraglutide
Outcome
DecreasePancreatic fat fraction
Study
n = 46
Analysis
Primary
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
3 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623208
09HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In people with obesity, body weight significantly improved over time across both calorie-restriction and liraglutide groups (time p < 0.001).
In plain wordsIn people with obesity, body weight improved over time across both calorie-restriction and liraglutide groups.
Peptide
Liraglutide
Outcome
Direction not reportedBody weight
Study
n = 46
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623209
10HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In people with obesity, liver fat fraction significantly improved over time across both calorie-restriction and liraglutide groups (time p < 0.001).
In plain wordsIn people with obesity, liver fat fraction improved over time across both calorie-restriction and liraglutide groups.
Peptide
Liraglutide
Outcome
Direction not reportedLiver fat fraction
Study
n = 46
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623210
11HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In people with obesity, visceral fat area significantly improved over time across both calorie-restriction and liraglutide groups (time p < 0.001).
In plain wordsIn people with obesity, visceral fat area improved over time across both calorie-restriction and liraglutide groups.
Peptide
Liraglutide
Outcome
Direction not reportedVisceral fat area
Study
n = 46
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623211
12HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In people with obesity, HbA1c significantly improved over time across both calorie-restriction and liraglutide groups (time p < 0.001).
In plain wordsIn people with obesity, HbA1c improved over time across both calorie-restriction and liraglutide groups.
Peptide
Liraglutide
Outcome
Direction not reportedHbA1c
Study
n = 46
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623212
13HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In people with obesity, HOMA2-IR significantly improved over time across both calorie-restriction and liraglutide groups (time p < 0.001).
In plain wordsIn people with obesity, HOMA2-IR improved over time across both calorie-restriction and liraglutide groups.
Peptide
Liraglutide
Outcome
Direction not reportedHOMA2-IR
Study
n = 46
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623213
14HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In people with obesity, ISIM significantly improved over time across both calorie-restriction and liraglutide groups (time p < 0.001).
In plain wordsIn people with obesity, ISIM improved over time across both calorie-restriction and liraglutide groups.
Peptide
Liraglutide
Outcome
Direction not reportedISIM
Study
n = 46
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Primary endpoint was the change in pancreatic fat fraction (PFF).
Summary · context
Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623214
15HumanNot a test of Liraglutide aloneNon-randomized trialOther
In the combined obesity cohort, change in HOMA2-IR was positively associated with change in body weight.
In plain wordsAcross calorie-restriction and liraglutide groups in people with obesity, HOMA2-IR changes were positively linked to body-weight changes.
Peptide
Liraglutide
Outcome
IncreaseAssociation of change in HOMA2-IR and body weight
Study
n = 46
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Regression analysis indicated that ΔHOMA2-IR was positively associated with Δweight and ΔLFF but negatively with ΔPFF, while ΔISIM was negatively associated with ΔVFA and positively with ΔPFF.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623215
16HumanNot a test of Liraglutide aloneNon-randomized trialOther
In the combined obesity cohort, change in HOMA2-IR was positively associated with change in liver fat fraction.
In plain wordsAcross calorie-restriction and liraglutide groups in people with obesity, HOMA2-IR changes were positively linked to liver-fat changes.
Peptide
Liraglutide
Outcome
IncreaseAssociation of change in HOMA2-IR and liver fat fraction
Study
n = 46
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Regression analysis indicated that ΔHOMA2-IR was positively associated with Δweight and ΔLFF but negatively with ΔPFF, while ΔISIM was negatively associated with ΔVFA and positively with ΔPFF.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623216
17HumanNot a test of Liraglutide aloneNon-randomized trialOther
In the combined obesity cohort, change in HOMA2-IR was negatively associated with change in pancreatic fat fraction.
In plain wordsAcross calorie-restriction and liraglutide groups in people with obesity, HOMA2-IR changes were inversely linked to pancreatic-fat changes.
Peptide
Liraglutide
Outcome
DecreaseAssociation of change in HOMA2-IR and pancreatic fat fraction
Study
n = 46
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Regression analysis indicated that ΔHOMA2-IR was positively associated with Δweight and ΔLFF but negatively with ΔPFF, while ΔISIM was negatively associated with ΔVFA and positively with ΔPFF.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623217
18HumanNot a test of Liraglutide aloneNon-randomized trialOther
In the combined obesity cohort, change in ISIM was negatively associated with change in visceral fat area.
In plain wordsAcross calorie-restriction and liraglutide groups in people with obesity, ISIM changes were inversely linked to visceral-fat changes.
Peptide
Liraglutide
Outcome
DecreaseAssociation of change in ISIM and visceral fat area
Study
n = 46
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Regression analysis indicated that ΔHOMA2-IR was positively associated with Δweight and ΔLFF but negatively with ΔPFF, while ΔISIM was negatively associated with ΔVFA and positively with ΔPFF.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623218
19HumanNot a test of Liraglutide aloneNon-randomized trialOther
In the combined obesity cohort, change in ISIM was positively associated with change in pancreatic fat fraction.
In plain wordsAcross calorie-restriction and liraglutide groups in people with obesity, ISIM changes were positively linked to pancreatic-fat changes.
Peptide
Liraglutide
Outcome
IncreaseAssociation of change in ISIM and pancreatic fat fraction
Study
n = 46
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Regression analysis indicated that ΔHOMA2-IR was positively associated with Δweight and ΔLFF but negatively with ΔPFF, while ΔISIM was negatively associated with ΔVFA and positively with ΔPFF.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide.
Summary · context
Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4173623219

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.